Literature DB >> 18065162

Effects of gabapentin on cocaine self-administration, cocaine-triggered relapse and cocaine-enhanced nucleus accumbens dopamine in rats.

Xiao-Qing Peng1, Xia Li, Jie Li, P Veeraraghavan Ramachandran, Pravin D Gagare, Debarshi Pratihar, Charles R Ashby, Eliot L Gardner, Zheng-Xiong Xi.   

Abstract

Gabapentin is a gamma-aminobutyric acid (GABA) analogue, with GABAmimetic pharmacological properties. Gabapentin is used for the treatment of seizures, anxiety and neuropathic pain. It has been proposed that gabapentin may be useful in the treatment of cocaine dependence. However, clinical trials with gabapentin have shown conflicting results, while preclinical studies are sparse. In the present study, we investigated the effects of gabapentin on intravenous cocaine self-administration and cocaine-triggered reinstatement of drug-seeking behavior, as well as on cocaine-enhanced dopamine (DA) in the nucleus accumbens (NAc). We found that gabapentin (25-200 mg/kg, i.p., 30 min or 2 h prior to cocaine) failed to inhibit intravenous cocaine (0.5 mg/kg/infusion) self-administration under a fixed-ratio reinforcement schedule or cocaine-triggered reinstatement of cocaine-seeking behavior. In vivo microdialysis showed that the same doses of gabapentin produced a modest increase (approximately 50%, p<0.05) in extracellular NAc GABA levels, but failed to alter either basal or cocaine-enhanced NAc DA. These data suggest that gabapentin is a weak GABA-mimic drug. At the doses tested, it has no effect in the addiction-related animal behavioral models here tested. This is in striking contrast to positive findings in the same animal models shown by another GABAmimetic--gamma-vinyl GABA (see companion piece to present article).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18065162      PMCID: PMC2574799          DOI: 10.1016/j.drugalcdep.2007.09.019

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  57 in total

Review 1.  The reinstatement model of drug relapse: history, methodology and major findings.

Authors:  Yavin Shaham; Uri Shalev; Lin Lu; Harriet de Wit; Jane Stewart
Journal:  Psychopharmacology (Berl)       Date:  2002-10-26       Impact factor: 4.530

Review 2.  Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function.

Authors:  Bankole A Johnson
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 3.  Preclinical evidence for GABAB agonists as a pharmacotherapy for cocaine addiction.

Authors:  David C S Roberts
Journal:  Physiol Behav       Date:  2005-09-15

4.  The simultaneous estimation of the influx and efflux blood-brain barrier permeabilities of gabapentin using a microdialysis-pharmacokinetic approach.

Authors:  Y Wang; D F Welty
Journal:  Pharm Res       Date:  1996-03       Impact factor: 4.200

5.  Gabapentin abuse in a cocaine user: implications for treatment?

Authors:  J S Markowitz; R Finkenbine; H Myrick; L King; W H Carson
Journal:  J Clin Psychopharmacol       Date:  1997-10       Impact factor: 3.153

6.  A microdialysis study on the mechanism of action of gabapentin.

Authors:  W Timmerman; M Bouma; J B De Vries; M Davis; B H Westerink
Journal:  Eur J Pharmacol       Date:  2000-06-09       Impact factor: 4.432

7.  Effects of ecopipam, a selective dopamine D1 antagonist, on smoked cocaine self-administration by humans.

Authors:  M Haney; A S Ward; R W Foltin; M W Fischman
Journal:  Psychopharmacology (Berl)       Date:  2001-06       Impact factor: 4.530

8.  Characterisation of [3H]gabapentin binding to a novel site in rat brain: homogenate binding studies.

Authors:  N Suman-Chauhan; L Webdale; D R Hill; G N Woodruff
Journal:  Eur J Pharmacol       Date:  1993-02-15       Impact factor: 4.432

9.  Gabapentin reduces cocaine use among addicts from a community clinic sample.

Authors:  Wilfrid Noel Raby; Siobhan Coomaraswamy
Journal:  J Clin Psychiatry       Date:  2004-01       Impact factor: 4.384

10.  Gabapentin maintenance decreases smoked cocaine-related subjective effects, but not self-administration by humans.

Authors:  Carl L Hart; Amie S Ward; Eric D Collins; Margaret Haney; Richard W Foltin
Journal:  Drug Alcohol Depend       Date:  2004-03-08       Impact factor: 4.492

View more
  8 in total

1.  Can the chronic administration of the combination of buprenorphine and naloxone block dopaminergic activity causing anti-reward and relapse potential?

Authors:  Kenneth Blum; Thomas J H Chen; John Bailey; Abdalla Bowirrat; John Femino; Amanda L C Chen; Thomas Simpatico; Siobhan Morse; John Giordano; Uma Damle; Mallory Kerner; Eric R Braverman; Frank Fornari; B William Downs; Cynthia Rector; Debmayla Barh; Marlene Oscar-Berman
Journal:  Mol Neurobiol       Date:  2011-09-24       Impact factor: 5.590

2.  α2δ-1 signaling in nucleus accumbens is necessary for cocaine-induced relapse.

Authors:  Sade Spencer; Robyn M Brown; Gabriel C Quintero; Yonatan M Kupchik; Charles A Thomas; Kathryn J Reissner; Peter W Kalivas
Journal:  J Neurosci       Date:  2014-06-18       Impact factor: 6.167

Review 3.  Cocaine-induced neuroadaptations in glutamate transmission: potential therapeutic targets for craving and addiction.

Authors:  Heath D Schmidt; R Christopher Pierce
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

Review 4.  Hypothesis-driven medication discovery for the treatment of psychostimulant addiction.

Authors:  Zheng-Xiong Xi; Eliot L Gardner
Journal:  Curr Drug Abuse Rev       Date:  2008-11

Review 5.  Anti-relapse medications: preclinical models for drug addiction treatment.

Authors:  Noushin Yahyavi-Firouz-Abadi; Ronald E See
Journal:  Pharmacol Ther       Date:  2009-08-13       Impact factor: 12.310

6.  Gamma-vinyl GABA increases nonvesicular release of GABA and glutamate in the nucleus accumbens in rats via action on anion channels and GABA transporters.

Authors:  Xiao-Qing Peng; Eliot L Gardner; Zheng-Xiong Xi
Journal:  Psychopharmacology (Berl)       Date:  2009-12-22       Impact factor: 4.530

7.  Involvement of the dopaminergic system in the reward-related behavior of pregabalin.

Authors:  Yusuf S Althobaiti; Farooq M Almutairi; Fahad S Alshehri; Ebtehal Altowairqi; Aliyah M Marghalani; Amal A Alghorabi; Walaa F Alsanie; Ahmed Gaber; Hashem O Alsaab; Atiah H Almalki; Alqassem Y Hakami; Turki Alkhalifa; Ahmad D Almalki; Ana M G Hardy; Zahoor A Shah
Journal:  Sci Rep       Date:  2021-05-19       Impact factor: 4.379

Review 8.  Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentary.

Authors:  Kenneth Blum; Amanda Lih Chuan Chen; Thomas J H Chen; Eric R Braverman; Jeffrey Reinking; Seth H Blum; Kimberly Cassel; Bernard W Downs; Roger L Waite; Lonna Williams; Thomas J Prihoda; Mallory M Kerner; Tomas Palomo; David E Comings; Howard Tung; Patrick Rhoades; Marlene Oscar-Berman
Journal:  Theor Biol Med Model       Date:  2008-11-12       Impact factor: 2.432

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.